Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

InspireMD, Inc. (II2.F)

2.2000
0.0000
(0.00%)
As of 8:05:14 AM GMT+2. Market Open.
Loading Chart for II2.F
  • Previous Close 2.2000
  • Open 2.2000
  • Bid 2.2200 x --
  • Ask 2.3600 x --
  • Day's Range 2.2000 - 2.2000
  • 52 Week Range 1.7800 - 3.4800
  • Volume 1,035
  • Avg. Volume 25
  • Market Cap (intraday) 70.325M
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6700
  • Earnings Date May 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.

www.inspiremd.com

85

Full Time Employees

December 31

Fiscal Year Ends

Recent News: II2.F

View More

Performance Overview: II2.F

Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

II2.F
14.06%
S&P 500 (^GSPC)
5.90%

1-Year Return

II2.F
24.29%
S&P 500 (^GSPC)
8.53%

3-Year Return

II2.F
4.41%
S&P 500 (^GSPC)
29.09%

5-Year Return

II2.F
77.26%
S&P 500 (^GSPC)
93.30%

Compare To: II2.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: II2.F

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    70.05M

  • Enterprise Value

    41.54M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.91

  • Price/Book (mrq)

    2.12

  • Enterprise Value/Revenue

    6.71

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -44.34%

  • Return on Equity (ttm)

    -84.68%

  • Revenue (ttm)

    7.01M

  • Net Income Avi to Common (ttm)

    -32.01M

  • Diluted EPS (ttm)

    -0.6700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    34.64M

  • Total Debt/Equity (mrq)

    6.48%

  • Levered Free Cash Flow (ttm)

    -11M

Research Analysis: II2.F

View More

Company Insights: II2.F

Research Reports: II2.F

View More